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Rob J. Hinchliffe, MD, FRCS, Peter J. E. Holt, PhD, FRCS, and
Matt M. Thompson, MD, FRCS, London, United Kingdom
Objective: This was a systematic review and meta-analysis of the mode of anesthesia and outcome after endovascular
aneurysm repair (EVAR).
Methods: Review methods were according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) guidelines. Published and unpublished literature was searched. The primary outcome was 30-day mortality.
Secondary outcomes were categorized for patient selection, perioperative outcomes, and postoperative outcomes.
Weighted mean differences (WMD) were calculated for continuous variables, such as length of stay, and pooled odds
ratios (OR) were calculated for discrete variables such as major morbidity.
Results: Ten studies of 13,459 patients given local anesthesia (LA) or general anesthesia (GA) were eligible for analysis.
There was no difference in 30-day mortality. The LA patients were older than the GA patients (WMD, 0.17; P  .006),
with an increased burden of cardiac (LA vs GA: OR, 1.28; P  .011) and respiratory (LA vs GA: OR, 1.28; P  .006)
comorbidity. LA EVAR was reported with shorter operative time (WMD, 0.54; P  .001) and hospital stay (WMD,
0.27; P  .001) vs GA. LA patients developed fewer postoperative complications than GA patients (OR, 0.54; P <
.001).
Conclusions: The absence of randomized data is a major hurdle to understanding the effect of anesthetic technique on
morbidity after EVAR. The data presented are encouraging in selected patients. The use of locoregional anesthesia for
EVAR should be further investigated with better reporting of aneurysm morphology to clarify its potential benefits and
identify the subgroups that will derive greatest benefit. ( J Vasc Surg 2012;56:510-9.)
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(Patients with abdominal aortic aneurysms (AAAs) have
a significant atherosclerotic burden and commonly have
extensive comorbidity.1 Endovascular aneurysm repair
(EVAR) represents the least invasive intervention available
for the treatment of this cohort. It entails a relatively minor
physiologic insult compared with open aneurysm repair
because aortic cross-clamping is avoided, resulting in less
severe hemodynamic changes and a lower incidence of
subclinical myocardial ischemia.2,3
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510The less invasive nature of EVAR is associated with
ower 30-day mortality than open repair,4 but surprisingly,
andomized data have demonstrated no difference in the
ate of adverse postoperative cardiac events.2,5 Although
he perioperative mortality of AAA repair has been greatly
educed by the advent of EVAR, improving postoperative
orbidity therefore remains an ongoing challenge. EVAR
nder locoregional anesthesia might represent one way to
urther minimize the physiologic effect of the operation.
Some reports have already demonstrated the feasibility
f this approach with excellent perioperative results,6,7 but
thers have not demonstrated any improvement in cardio-
ulmonary morbidity in patients undergoing EVAR with
ocoregional anesthesia,8 and the evidence as a whole has
ot been subjected to quantitative review. To our knowl-
dge, this article provides the first pooled analysis compar-
ng the perioperative and postoperative outcomes of EVAR
erformed under local (LA) or regional anesthesia (RA),
ith LA, defined as topical anesthesia with intravenous
edation, and regional anesthesia (RA), defined as spinal or
pidural anesthesia, compared with general anesthesia
GA), defined as standard induction and maintenance
gents.
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This was a systematic review that conformed to Preferred
Reporting Items for Systematic Reviews and Meta-Analysis
(PRISMA) guidelines. The population of interest was patients
undergoing EVAR in studies that compared outcomes between
patientsoperatedonunderGAwith thoseoperatedonunderLA
or RA.
Data sources. A systematic search of MEDLINE, Ex-
cerpta Medica Database (EMBASE), Web of Science, and Co-
Fig. Preferred Reporting Items for Systematic Reviews and M
used.33-53chrane Library (2011 Issue 4) databases was performed. The rlectronic search was supplemented by a search of material not
ormally published by commercial publishers or peer-reviewed
ournals, including the Conference Proceedings Citation Index
n the Web of Science. The reference lists of articles obtained
ere searched to identify further relevant citations. Finally, the
earch included the Current Controlled Trials Register (http://
ww.controlled-trials.com) and the Cochrane Database of
ontrolled Trials.
Search strategy. The search terms local anaesthesia,
nalysis (PRISMA) flow diagram depicts the search strategyeta-Aegional anaesthesia, epidural, spinal, endovascular, sur-
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August 2012512 Karthikesalingam et alTable I. Study characteristics, including exclusion criteria for each anesthetic technique
Study
Study
period
Sample
size Study design
Exclusion criteria for
LA/RA/GA
Anesthetic agent
(LA/RA/GA)
and techniquea
SIGN
level of
evidence
Geisbüsch,
2011
2007-2010 217 Retrospective
series
LA: history of difficult airway
management; patient
choice; retroperitoneal
approach; BMI  35 kg/
m2; sleep apnea; surgeon’s
preference; previous groin
surgery; severe GERD;
anxiety
Premedication: 1-2 mg
midazolam; H2 blocker;
glycopyrrolate
LA: 2% lidocaine; propofol for
sedation; fentanyl bolus
(50-150 g) for analgesia
RA and GA: not stated
2
Edwards, 2011 2005-2008 6009 Prospective
series
Not specified Not specified 2
Wax, 2010 2002-2007 522 Retrospective
series
Not specified LA and GA: not specified 2
RA: intrathecal tetracaine or
bupivacaine (12%, including
an epidural catheter)
Ruppert, 2006 1997-2004 5557 Prospective
series
Not specified Not specified 2
Falkensammer,
2006
2001-2002 25 Retrospective
series
Not specified Premedication: 2 mg
midazolam
2
RA (paravertebral blockade):
4 mL 0.5%-1.0%
ropivacaine with 1:200 to
1:400 adrenaline; propofol
infusion and fentanyl
boluses for sedation
GA: induced with propofol
and fentanyl, maintained
with isoflurane or
sevoflurane, vecuronium
and fentanyl
Verhoeven,
2005
1998-2003 239 Prospective
series
LA: retroperitoneal approach
to aorta or iliac arteries;
need for associated
abdominal procedures;
patient’s choice; anxiety;
groin re-explorations; BMI
 30
Occasional IV sedation with
0.05-0.2 mg/kg midazolam
or 25-75 g/kg propofol;
occasional analgesia with
50-150 g fentanyl bolus
or 0.1 g/kg/min
remifentanil infusion
2
LA: 4 mg/kg 1% lidocaine or
2 mg/kg 0.5% bupivacaine
with adrenaline
RA (spinal): 15-17.5 mg 0.5%
bupivacaine
RA (epidural): 3 mL 2%
lidocaine and 2 mg/kg
0.5% bupivacaine
GA: induced with 0.7-2.0
g/kg fentanyl or 0.2-0.6
g/kg sufentanil, and 0.1-
0.4 mg/kg etomidate;
maintained with 0.6 mg/kg
rocuronium and isoflurane
Parra, 2005 1997-1998 424 Prospective
series
Not specified LA: 10-20 mL 1% lidocaine,
with midazolam or propofol
for sedation
2
RA and GA: not specified
De Vergillo,
2002
1996-2000 229 Retrospective
series
Not specified Sedation with midazolam,
fentanyl and propofol
2
Bettex, 2001 1997-2001 91 Retrospective
series
LA: access via iliac artery Premedication: oral
flunitrazepam. Sedation:
midazolam, propofol,
fentanyl, sufentanil, or
2nicomorphine
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Volume 56, Number 2 Karthikesalingam et al 513gery, and the medical subject headings (MeSH) Anesthesia,
Spinal, Anesthesia, Epidural, Anaesthesia, Local, Endovas-
cular Procedures, Aortic Aneurysm, and Abdominal were
used in combination with Boolean operators and or or.
Two authors independently performed electronic searches
in November 2011.
Inclusion criteria. Duplicate articles were excluded
and the remaining abstracts reviewed for suitability. Ab-
stracts of the citations identified by the search were scruti-
nized by two of the authors (A.K., S.T.) to determine
eligibility for inclusion in the analysis. Inclusion criteria
specified studies comparing at least two of the three com-
monly used anesthetic techniques for EVAR: LA (eg, with
topical lidocaine/bupivacaine and intravenous sedation
with midazolam/propofol), RA (eg, with spinal or epidural
bupivacaine), and GA (eg, induction with intravenous
propofol/fentanyl and maintenance with inhaled isoflu-
rane/sevoflurane and intravenous vecuronium/fentanyl).
The specific reporting of outcomes for each type of anes-
thetic technique used was required for inclusion into the
present study.
The minimum information required from each article
was established before data abstraction. Data were ex-
tracted in duplicate (A.K., S.T.) using agreed proformas.
Differences were resolved by consensus. The quality of each
study was assessed using the Scottish Intercollegiate Guide-
lines Network (SIGN) checklists,9 which were used to
Table I. Continued.
Study
Study
period
Sample
size Study design
RA/
art
GA:
sp
Cao, 1999 1997-1998 115 Retrospective
series
GA:
no
BMI, Body mass index; COPD, chronic obstructive pulmonary disease; GA,
RA, regional anesthesia; SIGN, Scottish Intercollegiate Guidelines Network
aRegional anesthesia is defined as spinal or epidural.assign each study an indicative SIGN level of evidence.10 tPrimary and secondary outcomes. The primary out-
ome measure was defined as 30-day mortality. Secondary
utcome measures were extracted for patient selection
age, sex, comorbidity), perioperative information (com-
letion endoleak, percutaneous femoral access, operative
ime, intraoperative fluid requirements, number of patients
equiring blood transfusion), and postoperative informa-
ion (requirement for intensive care, postoperative compli-
ations, hospital length of stay).
Statistical analysis. Statistical analysis was performed
sing StatsDirect 2.5.7 software (StatsDirect, Altrincham,
K). Separate meta-analyses compared LA vs GA, RA vs
A, and LA vs RA. The weighted mean difference (WMD)
as calculated for the effect size of the type of anesthesia on
ontinuous variables such as age or length of stay. Pooled
dds ratios (ORs) and 95% confidence intervals (CIs) were
alculated for the effect of the type of anesthesia on discrete
ariables such as in-hospital mortality or overall morbidity.
Pooled outcomes were determined using random-
ffects models, as described by DerSimonian and Laird.11
tatistical heterogeneity was assessed descriptively by the I2
est.
The Egger test was used to assess for publication bias.
n the absence of publication bias, smaller trials display
reater variance in estimates of effect size than larger trials,
hich results in symmetric “funnel plots” of effect size
gainst standard error. In the presence of publication bias,
sion criteria for
A/RA/GA
Anesthetic agent
(LA/RA/GA)
and techniquea
SIGN
level of
evidence
ccess via femoral LA: max 500 mg 0.5-1%
lidocaine
sy, otherwise not RA (epidural): 0.5%
bupivacaine
GA: initiated with etomidate,
fentanyl and pancuronium;
maintained with isoflurane
and fentanyl or sufentanil
infusion
COPD, otherwise
ified
Premedication: 5-10 mg oral
diazepam
2
RA: 10 mL 0.5% bupivacaine
or 10 mL 0.75%
ropivacaine, with 2-4 mg
midazolam for sedation
GA: induction with 2-3 mg
midazolam, 2-3 g/kg of
fentanyl, 0.5-1 mg/kg of
propofol and 0.1 mg/kg
vecuronium; maintained
with mixture of nitrous
oxide and oxygen, 1.2%-
1.6% sevoflurane and
vecuronium
al anesthesia; GERD, gastroesophageal reflux disease; LA, local anesthesia;Exclu
L
GA: a
ery
epilep
ecified
severe
t spec
generhe funnel plot displays lateral asymmetry, which is tested
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effect estimate against precision).12 A significant result
from the Egger test with P  .05 would imply significant
Table II. Meta-analysis of data describing patient selection
Variable
Local anesthesia vs general
anesthesia
Age Significantly older
WMD (95% CI) P 0.17 (0.05-0.28) .006
Egger test P .317
Cochran Q P .123
I2, % 40.2
ASA 3 or 4 Significantly more common
Pooled OR (95% CI) P 1.25 (1.06-1.47) .009
Egger test P .156
Cochran Q P .893
I2, % 0
Respiratory disease Significantly more common
Pooled OR (95% CI) P 1.28 (1.07-1.52) .006
Egger test P .797
Cochran Q P .959
I2, % 0
Cardiac disease Significantly more common
Pooled OR (95% CI) P 1.28 (1.06-1.54) .011
Egger test P .885
Cochran Q P .406
I2, % 1.7
Renal disease Not significant
Pooled OR (95% CI) P 0.96 (0.63-1.45) .834
Egger test P .889
Cochran Q P .561
I2, % 0
Male sex Not significant
Pooled OR (95% CI) P 1.19 (0.72-1.97) .492
Egger test P .194
Cochran Q P .052
I2, % 51.9
Hypertension Not significant
Pooled OR (95% CI) P 0.91 (0.77-1.08) .276
Egger test P .821
Cochran Q P .705
I2, % 0
Diabetes Not significant
Pooled OR (95% CI) P 1 (0.57-1.76) .986
Egger test P .788
Cochran Q P .016
I2, % 67.1
Smoking Not significant
Pooled OR (95% CI) P 1.75 (0.29-10.67) .542
Egger test P .432
Cochran Q P .001
I2, % 98.8
Body mass index Not significant
WMD (95% CI) P 0.24 (0.55 to 0.06) .119
Egger test P NA
Cochran Q P .032
I2, % 70.9
Hyperlipidemia Not significant
Pooled OR (95% CI) P 0.76 (0.41-1.42) .392
Egger test P NA
Cochran Q P .06
I2, % 64.4
ASA, American Society of Anesthesiologists; CI, confidence interval; NA, npublication bias, which arises when trials with statistically rignificant results are preferentially published in English-
anguage journals and indexed in MEDLINE. This phe-
omenon can reduce the clinical applicability of pooled
each mode of anesthesia
Regional anesthesia vs
general anesthesia
Local anesthesia vs
regional anesthesia
Not significant Significantly older
0.03 (0.02 to 0.07) .274 0.09 (0.01-0.17) .021
.748 .567
.673 .448
0 0
Not significant Not significant
1.24 (0.53-2.88) .618 1.01 (0.44-2.3) .978
.595 .7
.001 .001
95 90.7
Significantly more common Not significant
1.63 (1.07-2.48) .023 0.73 (0.48-1.11) .142
.963 .365
.001 .015
82.3 64.6
Not significant Not significant
1.17 (0.96-1.42) .125 1.12 (0.72-1.74) .61
.3 .608
.296 .028
17 60.1
Significantly more common Not significant
1.79 (1.43-2.23) .001 0.58 (0.31-1.08) .085
.212 .445
.728 .208
0 30.3
Not significant Not significant
1.08 (0.74-1.57) .706 1.42 (0.78-2.59) .251
.671 .099
.034 .017
53.7 61.2
Not significant Not significant
0.98 (0.8-1.2) .824 0.87 (0.7-1.09) .227
.356 .868
.129 .334
37.6 12.6
Not significant Not significant
1.16 (0.58-2.32) .673 1.02 (0.77-1.36) .876
.91 .774
.001 .88
81.6 0
Not significant Significantly less common
1.7 (0.31-9.44) .543 0.69 (0.5-0.95) .024
.921 .688
.001 .117
99.2 45.8
Not significant Not significant
0.01 (0.09 to 0.06) .716 0.25 (0.77 to 0.27) .35
NA NA
.733 .002
0 83.8
Not significant Not significant
1.08 (0.93-1.26) .326 0.9 (0.42-1.94) .781
.974 NA
.554 .042
0 68.5
licable; OR, odds ratio; WMD, weighted mean difference.for
ot appesults from the meta-analysis.13
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ity from potential variation between the key outcomes
reported by component studies. The Cochran Q test was
used in this meta-analysis to investigate the null hypothesis
that all studies were evaluating the same effect by calculat-
ing the weighted sum of squared differences between indi-
vidual study effects and the pooled effect across studies. A
significant result of P  .05 would suggest considerable
differences among the results reported by component stud-
ies, necessitating a cautious approach toward interpreting
the pooled results.
RESULTS
After limits were applied, the searches identified 385
articles or abstracts. Of these, 34 abstracts contained
comparative data for EVAR under LA or RA compared
with EVAR under GA. After application of the inclusion
criteria to the full-text version of these articles, 10 stu-
Table III. Primary outcome measure
Outcome
Local anesthesia vs general
anesthesia
30-day mortality Not significant
Pooled OR (95% CI) P 0.7 (0.39-1.26) P  .235
Egger test P .39
Cochran Q P .774
I2, % 0
CI, Confidence interval; OR, odds ratio.
Table IV. Meta-analysis of perioperative outcomes for eac
Variable
Local anesthesia vs genera
anesthesia
Completion endoleak Not significant
Pooled OR (95% CI) P 0.54 (0.21-1.41) .211
Egger test P NA (too few strata)
Cochran Q P .072
I2, % 62
Operating time Significantly shorter
WMD (95% CI) P 0.54 (0.87 to 0.22) .0
Egger test P .19
Cochran Q P .001
I2, % 92.4
Fluid requirement Significantly less
WMD (95% CI) P 0.47 (.89 to .06) .026
Egger test P NA
Cochran Q P .066
I2, % 63.3
Percutaneous EVAR Not significant
Pooled OR (95% CI) P 0.83 (0.59-1.16) .268
Egger test P NA
Cochran Q P .277
I2, % NA
Patients needing blood transfusion Not significant
Pooled OR (95% CI) P 0.6 (0.26-1.37) .226
Egger test P NA
Cochran Q P .114
I2, % 53.9
CI, Confidence interval; NA, not applicable; OR, odds ratio; WMD, weighdies of 13,459 patients were eligible for pooled analy-is6,8,14-21 (Fig, PRISMA flow chart). The selected studies
ere classified as SIGN level 2 (nonrandomized). Data
ere extracted for case selection (Tables I and II), primary
utcome (Table III), secondary perioperative outcomes
Table IV), and secondary postoperative outcomes
Table V).
Primary outcomes. Six studies described in-hospital
ortality8,14,17,19,20 (Table III). There was no significant
ifference in 30-day mortality between LA vs GA (OR, 0.7;
5% CI, 0.39-1.26; P  .235), RA vs GA (OR, 0.82; 95%
I, 0.57-1.18; P .289), or LA vs RA (OR, 0.95; 95% CI,
.47-1.89; P  .879).
Secondary outcomes. Secondary outcomes were as-
essed for case selection, perioperative outcomes, and post-
perative outcomes.
. Case selection
1.1. Age. Seven studies reported that EVAR under LA
Regional anesthesia vs
general anesthesia
Local anesthesia vs
regional anesthesia
Not significant Not significant
0.82 (0.57-1.18) .289 0.95 (0.47-1.89) .879
.047 .638
.644 .89
0 0
de of anesthesia
Regional anesthesia vs general
anesthesia
Local anesthesia vs regional
anesthesia
Not significant Not significant
0.49 (0.12-1.91) .304 0.52 (0.1-2.75) .441
.49 NA (too few strata)
.001 .064
89.8 63.5
Significantly shorter Not significant
0.25 (0.39 to 0.11) .001 0.06 (0.31 to 0.19) .64
.156 .865
.002 .001
68.7 83
Not significant Not significant
0.56 (1.14 to 0.02) .058 0.36 (1.07 to 0.36) .327
.195 NA
.002 .001
80 86.5
Significantly less likely Not significant
0.58 (0.49-0.68) .001 2.14 (0.4-11.44) .373
NA NA
.321 .171
NA NA
Significantly less likely Not significant
0.7 (0.53-0.91) .009 1.02 (0.45-2.32) .96
NA NA
.548 .265
0 24.8
an difference.h mo
l
01occurred in a significantly older group than EVAR
2dds r
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.006),6,8,14-16,19 LA was used in a significantly
older population than RA (WMD, 0.09; 95% CI,
0.01-0.17; P  .021), but there was no difference
in the age of patients receiving RA compared with
GA (WMD, 0.03; 95% CI, –0.02 to 0.07; P 
.274; Table II).
1.2. Male sex. Seven studies reported no difference
in the sex of patients receiving LA vs GA (OR,
1.19; 95% CI, 0.72-1.97; P  .492), RA vs
GA (OR, 1.08; 95% CI, 0.74-1.57; P  .706), or
LA vs RA (OR, 1.42; 95% CI, 0.78-2.59; P 
.251)6,14-17,19,20 (Table II).
1.3. Cardiac disease. Cardiac disease was significantly
more common in LA patients than in GA patients
across six studies (OR, 1.28; 95% CI, 1.06-1.54;
P  .011).6,14,15,17,19,20 There was no difference
for RA vs GA (OR, 1.17; 95% CI, 0.96-1.42; P 
.125) or LA vs RA (OR, 1.12; 95% CI, 0.72-1.74;
P  .61; Table II).
1.4. Respiratory disease. Respiratory disease was more
prevalent in LA patients than GA patients in six
studies (OR, 1.28; 95% CI, 1.07-1.52; P 
.006)6,14,15,17,19,20 and more common in RA pa-
tients than GA patients (OR, 1.63; 95% CI, 1.07-
2.48; P  .023), but there was no difference
between LA and RA patients (OR, 0.73; 95% CI,
0.48-1.11; P  .142; Table II).
1.5. Renal disease. Information from six studies revea-
led renal disease was more common under RA
than GA (OR, 1.79; 95% CI, 1.43-2.23; P 
.001),6,14,15,17,19,20 but there was no difference in
Table V. Meta-analysis of postoperative outcomes for eac
Variable
Local anesthesia vs general
anesthesia
Length of stay Significantly shorter
WMD (95% CI) P 0.27 (0.43 to 0.1) .001
Egger test P .562
Cochran Q P .02
I2, % 62.7
Overall morbidity Significantly reduced
Pooled OR (95% CI) P 0.54 (0.41-0.72) .001
Egger test P NA
Cochran Q P .494
I2, % 0
Access complications Significantly fewer
Pooled OR (95% CI) P 0.5 (0.27-0.9) .022
Egger test P .955
Cochran Q P .224
I2, % 29.6
Intensive care required Significantly less likely
Pooled OR (95% CI) P 0.13 (0.07-0.23) .001
Egger test P .889
Cochran Q P .702
I2, % 0
CI, Confidence interval; ICU, intensive care unit NA, not applicable; OR, oLA vs GA (OR, 0.96; 95% CI, 0.63-1.45; P .834) or LA vs RA (OR, 0.58; 95% CI, 0.31-1.08;
P  .085; Table II).
1.6. American Society of Anesthesiologists III or IV.
Higher-risk patients according to the American
Society of Anesthesiologists (ASA) physical status
classification were more common under LA than
GA in five studies (OR, 1.25; 95% CI, 1.06-1.47;
P  .009).6,14,15,17,19 There was no difference for
LA vs RA (OR, 1.01; 95% CI, 0.44-2.3; P .978)
or RA vs GA (OR, 1.24; 95% CI, 0.53-2.88; P 
.618; Table II).
1.7. Body mass index, hypertension, diabetes, smoking,
and hyperlipidemia. There were no significant dif-
ferences in the distribution of these comorbidities
among the different anesthetic groups, although
smokers were less common under LA than RA
(OR, 0.69; 95% CI, 0.5-0.95; P .024; Table II).
. Perioperative outcomes
2.1. Completion endoleak. Five studies provided data on
completion endoleak.14,17,18,20,21 There was no
significant difference in completion endoleak be-
tween LA vs GA (OR, 0.54; 95% CI, 0.21-1.41;
P  .211), RA vs GA (OR, 0.49; 95% CI, 0.12-
1.91; P  .304), or LA vs RA (OR, 0.52; 95% CI,
0.1-2.75; P  .441; Table IV).
2.2. Operating time.Operating time was shorter under
LA than GA (WMD, –0.54; 95% CI, –0.87 to
–0.22; P .001)6,8,14-17,19,20 and under RA than
GA (WMD, –0.25; 95% CI, –0.39 to –0.11; P 
.001). There was no difference between LA and
RA (WMD, –0.06; 95% CI, –0.31 to 0.19; P 
de of anesthesia
egional anesthesia vs general
anesthesia
Local anesthesia vs regional
anesthesia
Significantly shorter Significantly shorter
13 (0.17 to 0.08)  .001 0.17 (0.3 to 0.04) .009
.959 .247
.786 .138
0 38.2
Significantly reduced Significantly reduced
78 (0.62-0.97) .026 0.68 (0.49-0.94) .019
.514 NA
.265 .979
24.4 0
Not significant Significantly fewer
1.08 (0.66-1.77) .746 0.38 (0.19-0.76) .006
.222 .027
.02 .095
62.8 49.3
Significantly less likely Significantly less likely
47 (0.38-0.58) .001 0.24 (0.12-0.49) .001
.548 NA
.906 .825
0 0
atio; WMD, weighted mean difference.h mo
R
0.
0.
0..64; Table IV).
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Volume 56, Number 2 Karthikesalingam et al 5172.3. Intraoperative fluid requirement. Less fluids were
given under LA than GA (WMD, –0.47; 95% CI,
–0.89 to –0.06; P  .026).8,14,16,20 There was no
difference in RA vs GA (WMD, –0.56; 95% CI,
–1.14 to 0.02; P  .058) or LA vs RA (WMD,
–0.36; 95% CI, –1.07 to 0.36; P .327; Table IV).
2.4. Percutaneous access.Therewas no difference between
LA vs GA (OR, 0.83; 95% CI, 0.59-1.16; P .268)
and LA vs RA (OR, 2.14; 95% CI, 0.4-11.44; P 
.373) in two studies,14,15 but percutaneous access
was less commonunderRA thanGA (OR, 0.58; 95%
CI, 0.49-0.68; P .001; Table IV).
2.5. Patients requiring blood transfusion. Three studies
showed no difference between LA vs GA (OR, 0.6;
95% CI, 0.26-1.37; P .0226) or RA vs GA (OR,
0.7; 95% CI, 0.53-0.91; P  .009).14,15,17 Blood
transfusion was less likely in LA vs RA (OR, 1.02;
95% CI, 0.45-2.32; P  .096; Table IV).
3. Postoperative outcomes
3.1. Hospital length of stay. Length of stay was signifi-
cantly shorter with LA than with GA (WMD,
–0.27; 95% CI, –0.43 to –0.1; P  .001) in six
studies,6,14-17,19 with RA compared with GA
(WMD, –0.13; 95% CI, –0.17 to –0.08; P 
.001), and with LA compared with RA (WMD,
–0.17; 95%CI, –0.3 to –0.04; P .009; Table V).
3.2. Morbidity. Morbidity was significantly rarer with
LA compared with GA (OR, 0.54; 95% CI, 0.41-
0.72; P  .001) in three studies,14,15,17 with RA
compared with GA (OR, 0.78; 95% CI, 0.62-0.97;
P  .026), and with LA compared with RA (OR,
0.68; 95% CI, 0.49-0.94; P  .019; Table V).
3.3. Access complications. Five studies reported that ac-
cess complications were significantly rarer with LA
compared with GA (OR, 0.5; 95% CI, 0.27-0.9;
P .022)14,15,17,19,20 and with LA compared with
RA (OR, 0.38; 95% CI, 0.19-0.76; P  .006).
There was no difference between RA and GA (OR,
1.08; 95% CI, 0.66-1.77; P  .746; Table V).
3.4. Requirement for intensive care. Intensive care re-
quirement was significantly less likely for LA vs GA
(OR, 0.13; 95% CI, 0.07-0.23; P  .001), for RA
vs GA (OR, 0.47; 95% CI, 0.38-0.58; P  .001),
and for LA vs RA (OR, 0.24; 95% CI, 0.12-0.49;
P  .001) across four studies (Table V).6,14,17,19
DISCUSSION
The main finding of this meta-analysis was that in
existing nonrandomized comparisons of EVAR under LA
or RA vs EVAR under GA, there was no demonstrable
difference in perioperative mortality. Secondary outcomes
showed that patients given LA/RA have been older and
with a higher ASA grade and an increased burden of pre-
existing cardiopulmonary disease, but that LA EVAR is
reported with shorter operative time, less intraoperative
fluid requirement, and fewer access vessel complications
than GA. LA patients had a significantly shorter hospital Ttay, a reduced requirement for intensive care, and fewer
ostoperative complications. Although these differences in
econdary outcomes were statistically significant, the
ooled effect sizes were clinically insignificant: LA patients
ere 0.17 years older than GA patients, with 1 minute’s
ifference in pooled operating time and less than half a day
f pooled difference in hospital stay.
The main limitation of these data is the presence of
onsiderable selection bias, which prevents any inference of
ausality. The quality of evidence was poor, and all studies
ere classified as SIGN level 2, indicating their status as
case control or cohort studies with a high risk of confound-
ng or bias and a significant risk that the relationship is not
ausal.” The shorter operative time and a reduction in access
essel complications seen with LA/RA are therefore likely to
e the result of unmeasured differences in patient selection;
or example, if GA is reserved for obese and anxious patients,
atients with morphologically complex AAAs, patients with
revious groin surgery, or those with small and calcified com-
on femoral vessels requiring extra-anatomic conduits for
evice delivery. Pooled analysis showed no difference in body
ass index according to mode of anesthesia, but a full inves-
igation of these unknown factors requires further data be-
ause objective exclusion criteria for LA were rarely provided
Table I). Furthermore, differences in case mix and the rate of
onservative management affect the population outcome
rom AAA repair,22 yet this information was not provided by
ny of the available literature.
Morphologic complexity is of greater importance than
hysiology in determining the difficulty and eventual out-
ome of EVAR,23-25 yet only two studies provided mor-
hologic information.17,19 The hypothesis that GA might
e preferred for technically challenging cases is supported
y the meta-analysis results, which demonstrated a signifi-
antly lower likelihood of access complications in LA
atients compared with GA patients. This is probably a
urrogate marker of the greater morphologic complexity
f those reserved for GA, although the European Col-
aborators on Stent-Graft Techniques for AAA and Tho-
acic Aortic Aneurysm and Dissection Repair (EURO-
TAR) study reported no significant difference in
neurysm neck diameter, neck length, or maximum sac
iameter between patients having LA and GA,17 and a
econd study reported an unvalidated scoring system for
orphologic complexity.19
It hasbeen suggested thatmortality andmajormorbidity are
imilar with LA or GA for EVAR and that comorbidities rather
han anesthetic technique might dictate these outcomes.26 In
ighly selectedpopulations,majormorbiditywasmore common
fter GA than LA/RA, and this findingmerits further investiga-
ion.Death at 30 days is rare in the endovascular era in appropri-
tely selected patients, with rates in the best centers at 1% to
%27,28 where EVAR is predominantly performed under GA.
his represents a benchmark that is unlikely to be surpassed by
lterations in anesthetic technique alone, and long-term reinter-
entions or aneurysm-related adverse events represent a more
ressing concern after EVAR than short-term mortality.23,28,29hat anesthetic techniquemight affect long-term reintervention
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studies of LA/RA vs GA for EVAR should aim to detect a
difference in postoperative morbidity and long-term reinterven-
tion rate rather than 30-day mortality. This would avoid the
pitfall of a randomized trial of LA in carotid surgery,30 which has
been criticized for a lackof clinical relevance causedby its original
aim to evaluate 30-daymortality rather thanmore common and
relevant end points.31
Comparative reintervention rates have not been pub-
lished in patients being operated on under LA/RA, but the
present study showed no difference in completion endoleak.
This finding is surprising, because EVARunder LA/RAposes
a number of technical challenges during stent graft deploy-
ment that might lower technical success rates compared with
GA in patients of equivalent complexity. For example, inferior
suspension of respiration during stent deployment and in-
creased bowel peristalsis can reduce the quality of intraopera-
tive imaging under LA,32 and the risk of patient movement
during painful stimuli is also a hazard.Manipulation of sheaths
or device delivery systems inside the iliac vessels can be painful,
and prolonged attempts at contralateral limb cannulation can
lead to ischemic limb pain. The resultant movement of the
patient further increases technical difficulty, which is not a
factor under GA. These theoretic considerations were not
supported by the observation of shorter operating time in LA
EVAR, although confounding factors are likely to have a
significant role.
Operator experience is likely to influence the choice of anes-
thesia andpercutaneousaccess aswell as theaccompanyingriskof
vascular complications. None of the reviewed literature categor-
ically related surgeons’ experience to operative access or anes-
thetic technique; the present literature does not provide convinc-
ing support for endovascular surgeons to alter their existing
practice. In keeping with the advancement of anesthetic tech-
niques in recent decades, morbidity and mortality attributable
solely to GA has become exceedingly rare, and no incidences of
this were reported in the studies reviewed.
In summary, it remains difficult to gauge the specific
proportion of post-EVAR morbidity attributable to the
type of anesthesia that is used. To enable causation of
morbidity to be attributed to the type of anesthetic, further
studies are required to compare EVAR under LA/RA with
EVAR under GA. Overall, the current evidence is insuffi-
ciently robust for vascular units to abandon their standard
practice. The absolute differences between anesthetic tech-
niques appear small even in the selected series. This meta-
analysis does not support suggestions that LA improves
outcomes from EVAR, and investigation of this hypothesis
will require unbiased, prospective, and randomized data.
CONCLUSIONS
All of the data comparing LA or RA EVAR with GA
EVAR come from nonrandomized studies. It was not pos-
sible to assess the confounding influence of morphologic
complexity allocated to GA or LA EVAR, although this is
an important determinant of EVAR outcomes. There was
no difference in 30-day mortality or completion endoleak,
but LA EVAR was reported with a shorter operative time,horter hospital stay, reduced requirement for intensive
are, and fewer postoperative complications. Pooled differ-
nces were predominantly clinically insignificant, and fur-
her studies incorporating morphologic data are required
o verify the advantages and disadvantages of LAEVAR and
o identify the patients likely to derive the greatest benefit.
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